Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [4101] Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients.
  [4102] Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction.
  [4103] Phase III two by two factorial comparison of doxorubicin and cyclophosphamide followed by a taxan vs. a taxan alone, and paclitaxel vs. docetaxel in operable node positive breast cancer – results of the first interim analysis of NSASBC02 trial.
  [4104] Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.
  [4105] Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer.
  [4107] Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer.
  [4108] Toxicity analysis of a phase III study evaluating FEC-Doc vs. FEC-Doc in combination with gemcitabine as adjuvant treatment for breast cancer – the SUCCESS-trial.
  [4109] Adjuvant chemotherapy for breast cancer – prognostic impact of relative dose-intensity.
  [4110] Feasibility of the sequential FEC 100-Taxotere chemotherapy regimen as an adjuvant or neoadjuvant treatment for breast cancer. Experience of a single institution.
  [4111] Relative dose intensity reduction in breast cancer adjuvant chemotherapy.
  [4112] Incidence and impact of abnormal liver function in patients receiving adjuvant chemotherapy for early breast cancer.
  [4113] Preliminary safety results from a multicenter phase II noncomparative two arm pilot of bevacizumab with anastrozole or fulvestrant as 1st line metastatic breast cancer therapy.
  [4115] Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.
  [4116] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.
  [4117] Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer.
  [4118] Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC).
  [4119] Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer.
  [4120] Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.
  [4121] Bevacizumab (BEV) and paclitaxel (PAC) every two weeks as first-line treatment for advanced breast cancer (ABC). Preliminary results.
  [4122] Fluvastatin has biologic effects on stage 0 and 1 breast cancer.
  [4124] A phase I study of an autologous GM-CSF-secreting breast cancer vaccine.
  [4125] The role of systemic therapies in the development of lung sequelae after conformal radiotherapy in breast cancer patients.
  [4126] a5b1 integrin mediates survival of breast cancer cells in 3-dimensional culture that can be specifically targeted for therapy.
  [4129] Matched-pair analysis of female and male breast cancer: a comprehensive cohort study.
  [4130] Male breast cancer: follow-up recommendations after surgery.
  [4132] Carcinoma of breast in males in Turkey: a Turkish oncology group study.
  [4134] Tumor location does not influence the survival effects of radiotherapy in node-negative breast cancer.
  [4136] Radiofrequency ablation of breast cancer lumpectomy cavities – a technique intended to increase negative margins after breast conservation surgery. From benchtop to clinical use.
  [4138] Local-regional and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies.
  [4139] Fibrin sealant for the prevention of axillary seroma formation after axillary lymph node disection. A prospective randomized study.
  [4140] Complications of methylene blue dye infiltration for sentinel lymph node biopsy in breast cancer.
  [4142] 3D imaging comparing implant vs. TRAM breast reconstruction.
  [4143] Impact of fat grafting the chest wall prior to implant reconstruction in high risk patients.
  [4145] Long-term follow-up results of endoscopy-assisted breast surgery (EBS) for early breast cancer.
  [4146] Intra-operative specimen sonography: a valuable tool to identify tumor free margins during breast-conserving therapy.
  [4148] Wise-pattern breast reconstruction: pocket augmentation using alloderm and a vascularized dermal-subcutaneous pedicle.
  [4150] Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients.
  [4151] Two-stage breast reconstruction using form-stable, anatomically shaped implants.
  [4152] Skin sparing mastectomy and immediate breast reconstruction: more indications with no increased in recurrences in breast cancer patients.
  [4153] Is there any benefit in routine wound drainage following mastectomy and axillary clearance?
  [4155] A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
  [4156] Low levels of both xanthine dehydrogenase and cellular retinol binding protein are responsible of the retinoic acid deficiency in malignant human mammary epithelial cells.
  [4157] Protein levels of NAD(P)H:quinone oxidoreductase 1 and p53 correlate in breast tumors.
  [4158] The role of ABCB1 transporter gene in breast cancer resistance.
  [4159] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
  [4160] Breast cancer, dermatofibromas and arsenic.
  [4161] Cyclin B as a prognostic factor in low-risk node negative breast cancer.
  [4162] A new enrichment model for high sensitivity detection and downstream analyses of circulating tumor cells in breast cancer patients.
  [4166] MM-111: a novel bispecific antibody targeting ErbB3 with potent anti-tumor activity in ErbB2 over-expressing malignancies.
  [4167] RANKL inhibition decreases the incidence of mammary adenocarcinomas in wild type (WT) and MMTV-RANK transgenic mice.
  [4171] Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved